Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M258Revenue (TTM) $M19.6Net Margin (%)-388.2Altman Z-Score4.7
Enterprise Value $M106EPS (TTM) $-1.1Operating Margin %-400.3Piotroski F-Score2
P/E(ttm)--Beneish M-Score-1.0Pre-tax Margin (%)-396.7Higher ROA y-yN
Price/Book1.810-y EBITDA Growth Rate %-1.8Quick Ratio10.7Cash flow > EarningsY
Price/Sales12.65-y EBITDA Growth Rate %-1.6Current Ratio10.7Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-38.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-43.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M70.6ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with SGMO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SGMOFirst Eagle Investment 2016-09-30 Sold Out $4.13 - $6.84
($5.09)
$ 3.65-28%Sold Out0
SGMOFirst Eagle Investment 2016-06-30 Reduce-0.01%$5.14 - $7.5
($6.37)
$ 3.65-43%Reduce -84.20%60,000
SGMOFirst Eagle Investment 2016-03-31 Add$4.91 - $9.13
($6.04)
$ 3.65-40%Add 89.86%379,727
SGMOFirst Eagle Investment 2015-09-30 Buy $5.64 - $10.86
($8.27)
$ 3.65-56%New holding200,000
SGMOJoel Greenblatt 2015-09-30 Sold Out $5.64 - $10.86
($8.27)
$ 3.65-56%Sold Out0
SGMOFirst Eagle Investment 2015-06-30 Sold Out -0.02%$10.35 - $15.68
($12.96)
$ 3.65-72%Sold Out0
SGMOJoel Greenblatt 2015-06-30 Buy $10.35 - $15.68
($12.94)
$ 3.65-72%New holding30,334
SGMOJoel Greenblatt 2015-03-31 Sold Out -0.0021%$12.64 - $18.54
($15.47)
$ 3.65-76%Sold Out0
SGMOJoel Greenblatt 2014-12-31 Buy $9.85 - $16.53
($12.15)
$ 3.65-70%New holding17,441
SGMOFirst Eagle Investment 2014-06-30 Add0.01%$11.71 - $17.95
($14.37)
$ 3.65-75%Add 34.10%536,380
SGMOFirst Eagle Investment 2014-03-31 Reduce-0.02%$13.25 - $23.86
($19.12)
$ 3.65-81%Reduce -52.81%400,000
SGMOFirst Eagle Investment 2013-09-30 Add0.01%$7.92 - $11.28
($9.95)
$ 3.65-63%Add 99.73%847,550
SGMOFirst Eagle Investment 2013-06-30 Add$7.31 - $10.65
($8.72)
$ 3.65-58%Add 41.45%424,350
SGMOFirst Eagle Investment 2013-03-31 Buy 0.01%$6.01 - $10.8
($8.89)
$ 3.65-59%New holding300,000
SGMOFirst Eagle Investment 2010-03-31 Sold Out $4.76 - $6.63
($5.63)
$ 3.65-35%Sold Out0
SGMOFirst Eagle Investment 2009-12-31 Buy $5.04 - $8.09
($5.87)
$ 3.65-38%New holding470
SGMOFirst Eagle Investment 2009-09-30 Sold Out -0.01%$4.26 - $9.03
($6.39)
$ 3.65-43%Sold Out0
SGMOFirst Eagle Investment 2009-06-30 Buy 0.01%$3.51 - $4.98
($4.2)
$ 3.65-13%New holding260,600
SGMOFirst Eagle Investment 2009-03-31 Sold Out -0.01%$2.99 - $5.05
($4.1)
$ 3.65-11%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SGMO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SGMO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LANPHIER EDWARD O IIPresident & CEO 2015-07-15Sell25,000$10.43-65view
Wolff Henry WardExec VP & CFO 2015-07-13Sell12,000$10-63.5view
LANPHIER EDWARD O IIPresident & CEO 2015-06-15Sell25,000$11.08-67.06view
Wolff Henry WardExec VP & CFO 2015-06-10Sell12,000$12.21-70.11view
ANDO DALE GVP, Therapeutic Dev. & CMO 2015-06-05Sell15,000$12.29-70.3view
RINGO WILLIAM RDirector 2015-06-03Sell2,200$12.44-70.66view
Gregory Philip DSVP of Research & CSO 2015-06-01Sell15,000$12.39-70.54view
LANPHIER EDWARD O IIPresident & CEO 2015-05-15Sell25,000$11.51-68.29view
Wolff Henry WardExec VP & CFO 2015-05-11Sell12,000$13.25-72.45view
ANDO DALE GVP, Therapeutic Dev. & CMO 2015-05-05Sell15,000$12.29-70.3view

Quarterly/Annual Reports about SGMO:

News about SGMO:

Articles On GuruFocus.com
Biogen or Bluebird: Which Will Lead in SCD? Apr 30 2015 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Nov 03 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) May 05 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Nov 06 2009 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Aug 03 2009 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) May 05 2009 

More From Other Websites
ETFs with exposure to Sangamo Therapeutics, Inc. : January 20, 2017 Jan 20 2017
SANGAMO THERAPEUTICS, INC Financials Jan 18 2017
Biotech Premarket Movers: SGMO, IPXL, PTLA Jan 13 2017
Biotech Premarket Movers: IPXL, SGMO, ARLZ Jan 11 2017
Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-318 Genome Editing... Jan 11 2017
Sangamo Therapeutics Presents Latest Advances In Zinc Finger Nuclease Platform Technology At... Jan 10 2017
SANGAMO BIOSCIENCES INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Jan 06 2017
Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development... Jan 06 2017
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene... Jan 05 2017
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene... Jan 05 2017
Sangamo BioSciences Announces Presentation At The 35th Annual J.P. Morgan Healthcare Conference Jan 04 2017
ETFs with exposure to Sangamo BioSciences, Inc. : December 21, 2016 Dec 21 2016
Is Preferred Apartment Communities Inc. (APTS) A Good Stock to Buy? Dec 12 2016
ETFs with exposure to Sangamo BioSciences, Inc. : December 9, 2016 Dec 09 2016
SANGAMO BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Dec 07 2016
Sangamo BioSciences Presents Hemophilia A Program Data At The 2016 American Society Of Hematology... Dec 05 2016
What Smart Money Thinks about EZCORP Inc (EZPW)? Dec 05 2016
Is Sangamo Biosciences, Inc. (SGMO) a Good Stock to Invest in? Dec 04 2016
Biogen Spinoff Gets Gene Therapy Drugs (BIIB, SGMO) Dec 02 2016
Sangamo's Genome Editing Program for Hemoglobinopathies to Transfer to Biogen's Spin-Off Bioverativ Dec 01 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)